More languages
More actions
m (→Controversies: renamed to →Corruption: , and rename a subhreader to be more accurate.) |
mNo edit summary |
||
| Line 33: | Line 33: | ||
==References== | ==References== | ||
<references /> | <references /> | ||
[[Category:Drug companies]] | |||
Latest revision as of 16:08, 17 September 2022
Eli Lilly and Company | |
|---|---|
 | |
| Industry | Pharmacy |
| Founder | Eli Lilly |
| Key people | David A. Ricks (Chairperson, President, & CEO) Anat Ashkenazi (Vice president & CFO)[1] |
| Ownership | Lilly Endowment, 11.6%[2] |
| Revenue | +US$22.319 billion (2019)[3] |
| Net income | +US$8.318 (2019)[3] |
| Total assets | -US$39.286 (2019)[3] |
| Website | |
| www.lilly.com | |
Eli Lilly and Company, often shortened to Eli Lilly, is a U.S-based pharmaceutical corporation.
Corruption[edit | edit source]
Bribery of Jury in Prozac Lawsuits[edit | edit source]
On July 20, 2019; Eli Lilly was found to have bribed the Jury and victims of mass shootings 20 million dollars, in multiple lawsuits against Eli Lily for Prozac being linked to increased violence in users, to hide evidence of Prozac increasing the rate of mass shootings.[4]
Unapproved promotion of Zyprexa[edit | edit source]
Between 1999 and 2005, Eli Lilly promoted Zyprexa in primary-care for treatment of Dementia and Alzheimer's Dementia, without the approval of the Food and Drug Administration.[5]
In 2007, Eli Lilly had been sued by the U.S government, for $1.415 billion, due to the unapproved promotion of Zyprexa in primary-care.[5]
References[edit | edit source]
- ↑ Jaimy Lee (9 February 2021). Lilly promotes Anat Ashkenazi to CFO, says previous CFO had 'inappropriate' communication with employees Market Watch. Archived from the original on 9 February 2021.
- ↑ Document.
- ↑ 3.0 3.1 3.2 Eli Lilly and Company 2019 Annual Report (19 February 2020).
- ↑ Andrew Wolfson (2019-09-12T12:33Z−07:00). "Prozac maker paid millions to secure favorable verdict in mass shooting lawsuit, victims say" Courier Journal.
- ↑ 5.0 5.1 "Eli Lilly and Company Agrees to Pay $1.415 Billion to Resolve Allegations [of] Off-label Promotion of Zyprexa" (2009-01-15). Office of Public Affairs.